Recombinant AAV Integration Is Not Associated with Hepatic Genotoxicity in Nonhuman Primates and Patients

Molecular Therapy

Volumn 24, Issue 6, 2016, Pages 1100-1105

  Gil Farina, Irene ^a   Fronza, Raffaele ^a   Kaeppel, Christine ^a,f   Lopez Franco, Esperanza ^b   Ferreira, Valerie ^c   D'Avola, Delia ^d,e   Benito, Alberto ^d,e   Prieto, Jesus ^d,e   Petry, Harald ^c   Gonzalez Aseguinolaza, Gloria ^b,e   Schmidt, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIQURE   (Netherlands)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e IdiSNA Navarra Institute for Health Research   (Spain)

^f Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADULT; ANIMAL TISSUE; ARTICLE; CASE REPORT; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN TISSUE; NONHUMAN; POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; DEPENDOPARVOVIRUS; DNA SEQUENCE; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETIC RECOMBINATION; GENETIC TRANSDUCTION; GENETICS; LIVER; MACACA FASCICULARIS; PHYSIOLOGY; PORPHYRIA, ACUTE INTERMITTENT; PROCEDURES;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER; MACACA FASCICULARIS; PORPHYRIA, ACUTE INTERMITTENT; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSDUCTION, GENETIC; VIRUS INTEGRATION;

EID: 84962744063     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.52     Document Type: Article

References (35)

1. Haurigot, V, Mingozzi, F, Buchlis, G, Hui, DJ, Chen, Y, Basner-Tschakarjan, E et al. (2010). Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther 18: 1318-1329.
2. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
3. Simonelli, F, Maguire, AM, Testa, F, Pierce, EA, Mingozzi, F, Bennicelli, JL et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650.
4. McCarty, DM, Young, SM Jr. and Samulski, RJ (2004). Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38: 819-845.
5. Gaj, T, Epstein, BE and Schaffer, DV (2016). Genome engineering using adenoassociated virus: basic and clinical research applications. Mol Ther 24: 458-464.
6. Inagaki, K, Lewis, SM, Wu, X, Ma, C, Munroe, DJ, Fuess, S et al. (2007). DNA palindromes with a modest arm length of greater, similar 20 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice. J Virol 81: 11290-11303.
7. Miller, DG, Petek, LM and Russel, DW. (2004). Human gene targeting by adenoassociated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol 23: 767-773.
8. Miller, DG, Petek, LM and Russell, DW (2004). Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 36: 767-773.
9. Miller, DG, Trobridge, GD, Petek, LM, Jacobs, MA, Kaul, R and Russell, DW (2005). Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 79: 11434-11442.
10. Nakai, H, Wu, X, Fuess, S, Storm, TA, Munroe, D, Montini, E et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79: 3606-3614.
11. Li, H, Malani, N, Hamilton, SR, Schlachterman, A, Bussadori, G, Edmonson, SE et al. (2011). Assessing the potential for AAV vector genotoxicity in a murine model. Blood 117: 3311-3319.
12. Gaudet, D, Méthot, J, Déry, S, Brisson, D, Essiembre, C, Tremblay, G et al. (2013). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: An open-label trial. Gene Ther 20: 361-369.
13. Kaeppel, C, Beattie, SG, Fronza, R, van Logtenstein, R, Salmon, F, Schmidt, S et al. (2013). A largely random AAV integration profile after LPLD gene therapy. Nat Med 19: 889-891.
14. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
15. Rosas, LE, Grieves, JL, Zaraspe, K, La Perle, KM, Fu, H and McCarty, DM (2012). Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther 20: 2098-2110.
16. Bell, P, Moscioni, AD, McCarter, RJ, Wu, D, Gao, G, Hoang, A et al. (2006). Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 14: 34-44.
17. Zhong, L, Malani, N, Li, M, Brady, T, Xie, J, Bell, P et al. (2013). Recombinant adenoassociated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther 24: 520-525.
18. Donsante, A, Miller, DG, Li, Y, Vogler, C, Brunt, EM, Russell, DW et al. (2007). AAV vector integration sites in mouse hepatocellular carcinoma. Science 317: 477.
19. Wang, PR, Xu, M, Toffanin, S, Li, Y, Llovet, JM and Russell, DW (2012). Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci USA 109: 11264-11269.
20. Chandler, RJ, LaFave, MC, Varshney, GK, Trivedi, NS, Carrillo-Carrasco, N, Senac, JS et al. (2015). Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest 125: 870-880.
21. Walia, JS, Altaleb, N, Bello, A, Kruck, C, LaFave, MC, Varshney, GK et al. (2015). Longterm correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. Mol Ther 23: 414-422.
22. Nault, JC, Datta, S, Imbeaud, S, Franconi, A, Mallet, M, Couchy, G et al. (2015). Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47: 1187-1193.
23. Hüser, D, Gogol-Döring, A, Chen, W and Heilbronn, R (2014). Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing. J Virol 88: 11253-11263.
24. Büning, H and Schmidt, M (2015). Adeno-associated Vector Toxicity-To Be or Not to Be Mol Ther 23: 1673-1675.
25. Kustikova, OS, Baum, C and Fehse, B (2008). Retroviral integration site analysis in hematopoietic stem cells. Methods Mol Biol 430: 255-267.
26. Brady, T, Roth, SL, Malani, N, Wang, GP, Berry, CC, Leboulch, P et al. (2011). A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res 39: e72.
27. Schmidt, M, Schwarzwaelder, K, Bartholomae, C, Zaoui, K, Ball, C, Pilz, I et al. (2007). High-resolution insertion-site analysis by linear amplification-mediated PCR (LAMPCR). Nat Methods 4: 1051-1057.
28. Pañeda, A, Lopez-Franco, E, Kaeppel, C, Unzu, C, Gil-Royo, AG, D'Avola, D et al. (2013). Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: A potential therapy for acute intermittent porphyria. Hum Gene Ther 24: 1007-1017.
29. Gibbs, AJ and McIntyre, GA (1970). The diagram, a method for comparing sequences. Its use with amino acid and nucleotide sequences. Eur J Biochem 16: 1-11.
30. Presson, AP, Kim, N, Xiaofei, Y, Chen, IS and Kim, S (2011). Methodology and software to detect viral integration site hot-spots. BMC Bioinformatics 12: 367.
31. Schröder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
32. Gabriel, R, Kutschera, I, Bartholomae, C, von Kalle, C and Schmidt, M (2014). Linear amplification mediated PCR-localization of genetic elements and characterization of unknown flanking DNA. J. Vis. Exp. 25: e51543.
33. Nowrouzi, A, Penaud-Budloo, M, Kaeppel, C, Appelt, U, Le Guiner, C, Moullier, P et al. (2012). Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 20: 1177-1186.
34. Abel, U, Deichmann, A, Bartholomae, C, Schwarzwaelder, K, Glimm, H, Howe, S et al. (2007). Real-time definition of non-randomness in the distribution of genomic events. PLoS One 2: e570.
35. Wu, X, Luke, BT and Burgess, SM (2006). Redefining the common insertion site. Virology 344: 292-295.